StocksMedium•9 October 2026•
1 min read
Teva Shares Rise Following FDA Approval of New Schizophrenia Treatment
Key Facts
1The US FDA has approved a new once-monthly schizophrenia treatment developed by Teva.
The US Food and Drug Administration (FDA) has approved a new once-monthly injectable treatment for schizophrenia developed by Teva Pharmaceutical Industries. According to investing.com, the regulatory milestone triggered a rise in the company's share price during premarket trading as it introduces a new long-acting option for patients.
The approval serves as a major fundamental catalyst for Teva within the healthcare sector, strengthening its clinical product pipeline. Teva shares moved in a bullish direction following the announcement, reflecting the significance of the regulatory clearance for the company's future growth.